Efficacy and Safety of Intravitreal Injection of Bevacizumab with and Without Oral Curcumin
Efficacy and Safety of Intravitreal Injection of Bevacizumab with and Without Oral Curcumin in Diabetic Macular Edema
Isfahan University of Medical Sciences
52 participants
Oct 10, 2021
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate the effectiveness of adding curcumin oral treatment to bevacizumab intravitreal injection in patients with central macular edema. A blind study and a randomized and controlled clinical trial are conducted on diabetic patients with macular edema. The patients are divided into two intervention groups (bevacizumab + curcumin) and control (bevacizumab + placebo). The evaluation of the central thickness of the macula and the evaluation of the central volume of the macula are the primary goals and the evaluation of the best visual acuity of the patient is the secondary goal.
Eligibility
Inclusion Criteria2
- Patients with center-involving macular edema with macular center thickness more than 300 microns in OCT 2-Patients who did not receive intravitreal bevacizumab in the last 3 months and intravitreal corticosteroids in the last 6 months.
- - The amount of BCVA should not be <20/400. 4-Consent to participate in the study
Exclusion Criteria12
- Other retinal diseases except for DME and macular edema due to other causes including uveitis, epiretinal membrane, central retinal vein occlusion, and...
- Existence of proliferative diabetic retinopathy and patients with a history of vitrectomy
- Patients with glaucoma, vitreous hemorrhage, age-related macular degeneration (ARMD)
- Media opacities that limit the interpretation of diagnostic tests
- Surgery or procedure 3 months before starting treatment
- Pregnancy or breastfeeding
- History of allergy to curcumin
- Use of warfarin
- Changing the patient's clinical diagnosis or the need for surgical interventions in the course of the disease
- Change in the patient's general health condition
- Absence of patient referrals
- Lack of consent to continue treatment and follow-up
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
According to the recommendation of the American Association of Ophthalmologists, intravitreal injection of bevacizumab with a standard dose of 1.25mg/0.05ml in each group will be performed three times consecutively at one-month intervals. In the simultaneous intervention group, patients will take daily curcumin tablets (sinacurcumin product) at a dose of 40 mg twice a day for three months (at the same time as the start of bevacizumab intravitreal injection treatment).
Intravitreal injection of bevacizumab with a standard dose of 1.25mg/0.05ml in each group will be performed three times consecutively at one-month intervals. In the control group, patients will be taking daily placebo tablets twice a day for three months (at the same time as the start of bevacizumab intravitreal injection treatment).
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06595355